Gyre Therapeutics, Inc. (GYRE) Net margin 2017–2025
Gyre Therapeutics, Inc. (GYRE) net profit margin by fiscal year — reported net income divided by reported revenue.
8.5%FY2025 · since FY2017: -2118.0% → 8.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 8.5% | -8.4 pp |
| FY2024 | 16.9% | +92.3 pp |
| FY2023 | -75.3% | -79.6 pp |
| FY2022 | 4.2% | +1202.5 pp |
| FY2021 | -1198.3% | -929.8 pp |
| FY2020 | -268.5% | — |
| FY2018 | -500916.7% | -498798.7 pp |
| FY2017 | -2118.0% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More GYRE financial trends
GYRE RevenueGYRE Net incomeGYRE Gross profitGYRE Gross marginGYRE Operating incomeGYRE Operating marginGYRE Operating cash flowGYRE Free cash flowGYRE Capital expendituresGYRE Return on equityGYRE Stock buybacksGYRE Dividends paidGYRE Total assetsGYRE Total liabilitiesGYRE Shareholders’ equityGYRE overview →